EyePoint, Inc. (FRA:PV3B)

Market Cap	1.16B
Revenue (ttm)	36.09M
Net Income (ttm)	-175.36M
Shares Out	n/a
EPS (ttm)	-2.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	75
Open	13.90
Previous Close	14.17
Day's Range	13.89 - 13.98
52-Week Range	3.53 - 15.32
Beta	n/a
RSI	57.79
Earnings Date	Mar 2, 2026

About EyePoint

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degenerati...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 165
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PV3B

Financial Performance

In 2024, EyePoint's revenue was $43.27 million, a decrease of -5.97% compared to the previous year's $46.02 million. Losses were -$130.87 million, 84.9% more than in 2023.

Financial numbers in USD